Literature DB >> 30327369

Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma.

Tilmann Bochtler1,2,3, Maximilian Merz1, Thomas Hielscher4, Martin Granzow2,5, Korbinian Hoffmann1, Alwin Krämer1,3, Marc-Steffen Raab1, Jens Hillengass1,6, Anja Seckinger1,2, Christoph Kimmich1,2, Tobias Dittrich1,2,3, Carsten Müller-Tidow1, Dirk Hose1, Hartmut Goldschmidt1,7, Ute Hegenbart1,2, Anna Jauch2,5, Stefan O Schönland1,2.   

Abstract

Analysis of intraclonal heterogeneity has yielded insights into the clonal evolution of hematologic malignancies. We compared the clonal and subclonal compositions of the underlying plasma cell dyscrasia in 544 systemic light chain amyloidosis (PC-AL) patients with 519 patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), or symptomatic MM; ie, PC-non-AL patients). Using interphase fluorescence in situ hybridization, subclones were stringently defined as clone size below two thirds of the largest clone and an absolute difference of ≥30%. Subclones were found less frequently in the PC-AL group, at 199 (36.6%) of 544 as compared with 267 (51.4%) of 519 in the PC-non-AL group (P < .001), and were not associated with the stage of plasma cell dyscrasia in either entity. In both groups, translocation t(11;14), other immunoglobulin heavy chain translocations, and hyperdiploidy were typically found as main clones, whereas gain of 1q21 and deletions of 8p21, 13q14, and 17p13 were frequently found as subclones. There were no shifts in the subclone/main clone ratio depending on the MGUS, SMM, or MM stage of plasma cell dyscrasia. In multivariate analysis, t(11;14) was associated with lower rates of subclone formation and hyperdiploidy with higher rates. PC-AL itself lost statistical significance, demonstrating that the lower subclone frequency in AL is a reflection of its exceptionally high t(11;14) frequency. In summary, the subclone patterns in PC-AL and PC-non-AL are closely related, implying that subclone formation depends on the main cytogenetic categories and is independent of disease entity and stage.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2018        PMID: 30327369      PMCID: PMC6199662          DOI: 10.1182/bloodadvances.2018023200

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  39 in total

1.  Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.

Authors:  Angela Dispenzieri; Morie A Gertz; Robert A Kyle; Martha Q Lacy; Mary F Burritt; Terry M Therneau; Joseph P McConnell; Mark R Litzow; Dennis A Gastineau; Ayalew Tefferi; David J Inwards; Ivana N Micallef; Stephen M Ansell; Luis F Porrata; Michelle A Elliott; William J Hogan; S Vincent Rajkumar; Rafael Fonseca; Philip R Greipp; Thomas E Witzig; John A Lust; Steven R Zeldenrust; Denise S Snow; Susan R Hayman; Christopher G A McGregor; Allan S Jaffe
Journal:  Blood       Date:  2004-03-25       Impact factor: 22.113

2.  Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14).

Authors:  Tilmann Bochtler; Ute Hegenbart; Christiane Heiss; Axel Benner; Marion Moos; Anja Seckinger; Stephanie Pschowski-Zuck; Désirée Kirn; Kai Neben; Claus R Bartram; Anthony D Ho; Hartmut Goldschmidt; Dirk Hose; Anna Jauch; Stefan O Schonland
Journal:  Blood       Date:  2011-02-10       Impact factor: 22.113

3.  Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma.

Authors:  S Wuilleme; N Robillard; L Lodé; F Magrangeas; H Beris; J-L Harousseau; J Proffitt; S Minvielle; H Avet-Loiseau
Journal:  Leukemia       Date:  2005-02       Impact factor: 11.528

Review 4.  Genomic heterogeneity in multiple myeloma.

Authors:  Raphaël Szalat; Nikhil C Munshi
Journal:  Curr Opin Genet Dev       Date:  2015-05-16       Impact factor: 5.578

5.  Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.

Authors:  Jan B Egan; Chang-Xin Shi; Waibhav Tembe; Alexis Christoforides; Ahmet Kurdoglu; Shripad Sinari; Sumit Middha; Yan Asmann; Jessica Schmidt; Esteban Braggio; Jonathan J Keats; Rafael Fonseca; P Leif Bergsagel; David W Craig; John D Carpten; A Keith Stewart
Journal:  Blood       Date:  2012-04-23       Impact factor: 22.113

6.  Clonal competition with alternating dominance in multiple myeloma.

Authors:  Jonathan J Keats; Marta Chesi; Jan B Egan; Victoria M Garbitt; Stephen E Palmer; Esteban Braggio; Scott Van Wier; Patrick R Blackburn; Angela S Baker; Angela Dispenzieri; Shaji Kumar; S Vincent Rajkumar; John D Carpten; Michael Barrett; Rafael Fonseca; A Keith Stewart; P Leif Bergsagel
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

Review 7.  The genetic architecture of multiple myeloma.

Authors:  Gareth J Morgan; Brian A Walker; Faith E Davies
Journal:  Nat Rev Cancer       Date:  2012-04-12       Impact factor: 60.716

8.  Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study.

Authors:  Tilmann Bochtler; Ute Hegenbart; Christina Kunz; Axel Benner; Christoph Kimmich; Anja Seckinger; Dirk Hose; Hartmut Goldschmidt; Martin Granzow; Peter Dreger; Anthony D Ho; Anna Jauch; Stefan O Schönland
Journal:  Blood       Date:  2016-06-02       Impact factor: 22.113

9.  Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability.

Authors:  Tilmann Bochtler; Ute Hegenbart; Friedrich W Cremer; Christiane Heiss; Axel Benner; Dirk Hose; Marion Moos; Jelena Bila; Claus R Bartram; Anthony D Ho; Hartmut Goldschmidt; Anna Jauch; Stefan O Schonland
Journal:  Blood       Date:  2008-02-27       Impact factor: 22.113

10.  Genetics and cytogenetics of multiple myeloma: a workshop report.

Authors:  Rafael Fonseca; Bart Barlogie; Regis Bataille; Christian Bastard; P Leif Bergsagel; Marta Chesi; Faith E Davies; Johannes Drach; Philip R Greipp; Ilan R Kirsch; W Michael Kuehl; Jesus M Hernandez; Stephane Minvielle; Linda M Pilarski; John D Shaughnessy; A Keith Stewart; Herve Avet-Loiseau
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701

View more
  10 in total

1.  Differences in the cytogenetic underpinnings of AL amyloidosis among African Americans and Caucasian Americans.

Authors:  Andrew Staron; Luke Zheng; Gheorghe Doros; Vaishali Sanchorawala
Journal:  Blood Cancer J       Date:  2022-07-04       Impact factor: 9.812

2.  Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma.

Authors:  Maximilian Merz; Thomas Hielscher; David Schult; Elias K Mai; Marc S Raab; Jens Hillengass; Anja Seckinger; Dirk Hose; Martin Granzow; Anna Jauch; Hartmut Goldschmidt
Journal:  Leukemia       Date:  2019-11-11       Impact factor: 11.528

3.  AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival.

Authors:  Michael Ozga; Qiuhong Zhao; Don Benson; Patrick Elder; Nita Williams; Naresh Bumma; Ashley Rosko; Maria Chaudhry; Abdullah Khan; Srinivas Devarakonda; Rami Kahwash; Ajay Vallakati; Courtney Campbell; Samir V Parikh; Salem Almaani; Jason Prosek; Jordan Bittengle; Katherine Pfund; Samantha LoRusso; Miriam Freimer; Elyse Redder; Yvonne Efebera; Nidhi Sharma
Journal:  Cancer Med       Date:  2020-12-21       Impact factor: 4.452

4.  Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.

Authors:  Vikram J Premkumar; Suzanne Lentzsch; Samuel Pan; Divaya Bhutani; Joshua Richter; Sundar Jagannath; Michaela Liedtke; Arnaud Jaccard; Ashutosh D Wechalekar; Raymond Comenzo; Vaishali Sanchorawala; Bruno Royer; Michael Rosenzweig; Jason Valent; Stefan Schönland; Rafael Fonseca; Sandy Wong; Prashant Kapoor
Journal:  Blood Cancer J       Date:  2021-01-11       Impact factor: 11.037

5.  Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis.

Authors:  Zuzana Chyra; Tereza Sevcikova; Petr Vojta; Janka Puterova; Lucie Brozova; Katerina Growkova; Jana Filipova; Martina Zatopkova; Sebastian Grosicki; Agnieszka Barchnicka; Wieslaw Wiktor Jedrzejczak; Anna Waszczuk-Gajda; Alexandra Jungova; Aneta Mikulasova; Marian Hajduch; Martin Mokrejs; Ludek Pour; Martin Stork; Lubica Harvanova; Martin Mistrik; Gabor Mikala; Pawel Robak; Anna Czyz; Jakub Debski; Lidia Usnarska-Zubkiewicz; Artur Jurczyszyn; Lukas Stejskal; Gareth Morgan; Fedor Kryukov; Eva Budinska; Michal Simicek; Tomas Jelinek; Matous Hrdinka; Roman Hajek
Journal:  Haematologica       Date:  2021-02-01       Impact factor: 9.941

Review 6.  Genome Instability in Multiple Myeloma: Facts and Factors.

Authors:  Anna Y Aksenova; Anna S Zhuk; Artem G Lada; Irina V Zotova; Elena I Stepchenkova; Ivan I Kostroma; Sergey V Gritsaev; Youri I Pavlov
Journal:  Cancers (Basel)       Date:  2021-11-26       Impact factor: 6.639

7.  Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement.

Authors:  Natalie Berghaus; Sarah Schreiner; Martin Granzow; Carsten Müller-Tidow; Ute Hegenbart; Stefan O Schönland; Stefanie Huhn
Journal:  PLoS One       Date:  2022-02-25       Impact factor: 3.240

Review 8.  Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications.

Authors:  Linchun Xu; Yongzhong Su
Journal:  Exp Hematol Oncol       Date:  2021-07-20

Review 9.  Hunting down the dominating subclone of cancer stem cells as a potential new therapeutic target in multiple myeloma: An artificial intelligence perspective.

Authors:  Lisa X Lee; Shengwen Calvin Li
Journal:  World J Stem Cells       Date:  2020-08-26       Impact factor: 5.326

Review 10.  Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis.

Authors:  Giovanni Palladini; Paolo Milani; Fabio Malavasi; Giampaolo Merlini
Journal:  Cells       Date:  2021-03-04       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.